Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Business Wire (Press Release) 16h
WuXi AppTec added to Dow's 1260H list: The BIOSECURE Act clock is running JD Supra 7d Pentagon China Politics Pharma All sources
[BIO USA 2026] China’s biotech rise puts Korea on notice: KoreaBIO VP Korea Biomedical Review 12h San Diego Biotech Pharma All sources
HK plays key role in mainland tech firms' global expansion: official Global Times 2d Hong Kong China Chinese Economy All sources
Pfizer's Seagen-derived ADC pipeline suffers a setback pharmaphorum 2h Lung Cancer Pfizer Mergers and Acquisitions
Upadacitinib effective in refractory perianal Crohn’s disease, real-world data shows Hospital Pharmacy Europe 3h Inflammatory Bowel Disease
STAT Plus: Gene-editing startup launches with $230 million and a Chinese licensing deal STAT 1h CRISPR/Gene Editing Pharma Biotechnology
RedHill Biopharma announces closing of up to $19.4 Million private placement PR Newswire (Press Release) 16h Inflammatory Bowel Disease Stock Market (US) Intellectual Property
STAT Plus: FDA to launch pilot program to speed up early-stage clinical trials STAT 21h FDA Pharma China Politics
Alabama’s BIO International delegation to promote state’s investment, opportunities Alabama Daily News 1d Biotechnology Pharma Alabama
SpaceX IPO'd, and Anthropic and OpenAI could go public in 2026. Should you buy all three? The Motley Fool 2h Elon Musk SpaceX AI All sources
NSE IPO: 10 key risks investors should know from the DRHP Mint 1d Jio Platforms Stock Markets (India) India All sources
Waterways Leisure Tourism IPO sees a slow response on Day 1 so far. Should you subscribe? The Economic Times 5h Waterways Leisure Tourism IPO All sources
Turtlemint Fintech Solutions IPO Day 3: Should you subscribe as issue ends today? Check GMP, review, other key details Mint 8h All sources
